This release came in from my pharmacist friend in

Urgent Trade Alert:
ScripsAmerica, Inc (SCRC)

ScripsAmerica, Inc (SCRC) made a 350% move from late June to Early July of 2013. That move started with an initial thrust higher over a period of six trading sessions.

Over the past week, SCRC has made a move higher that looks nearly identical to the one that started the 350% climb.

Click here to view chart.

Disclaimer: The past is no guarantee of the future but we urge you to watch SCRC this morning. OTC stocks are highly risky and you could lose your entire investment capital. See full disclaimer below.

ScripsAmerica, Inc (SCRC) may be getting ready to retest the July $1.05 high.

Here's what could be causing all the recent interest in the stock:

• SCRC has the exclusive distribution rights for the new children's pain reliever and fever reducer RapiMed®. See their website at http://rapimeds.com
  



• SCRC has recently received $2 million in funding to produce the cutting-edge RapiMed® product and fund future operations.
  



• SCRC is getting ready to bring RapiMed® to store shelves throughout the United States
  



• SCRC is in active negotiations to distribute RapiMed® in China the most populous country on earth. You may wonder why China, but it appears Chinese love "Made in USA" labels on items such as Medicines.
  



• SCRC announced new strategic alliances that will provide a major increase in its domestic and international distribution reach.

The promise of a new shelf-ready drug, coupled with a viable expansion strategy may be causing investors to buy today in anticipation of RapiMed's rollout.

If SCRC moves from its current price to recent resistance - which is half the distance to the recent high - the move could represent a potential 100% profit in the matter of just a few days.

Market Authority plans to follow SCRC for the next 12 months and we will keep you posted on new press releases, movement in the stock and future trading opportunities as they present themselves.